Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEagle Eye Regulatory News (EYE)

Share Price Information for Eagle Eye (EYE)

Share Price is delayed by 15 minutes
Get Live Data
480.00    7.50 (1.59%)
Bid:
470.00
Ask:
490.00
Spread: 20.00 (4.255%)
Market Cap: £145.07m
EYE Live PriceLast checked at - London Stock Exchange

Intraday Eagle Eye Share Chart

Issue of share options

10 Nov 2017 16:03

RNS Number : 2250W
Eagle Eye Solutions Group PLC
10 November 2017
Β 

10 November 2017

Β 

Eagle Eye Solutions Group plc

("Eagle Eye", the "Group", or the "Company")

Β 

Issue of share options

Β 

Eagle Eye, the SaaS technology company that allows businesses to create a real-time connection with their customers. announces that the following options over ordinary shares of 1p each in Eagle Eye ("Ordinary Shares") were granted on 9 November 2017 to the following Executive Directors and senior personnel of Eagle Eye, as follows:

Β 

Director/Senior Personnel

Role

Number of Ordinary Shares subject to option grant

Total number of Ordinary Shares under option post grant

% of existing issued share capital

Tim Mason

CEO

305,550

970,103

3.8%

Steve Rothwell

CTO

47,527

763,695

3.0%

Lucy Sharman-Munday

CFO

47,527

303,492

1.2%

Helen Slaven

CSO

47,527

254,837

1.0%

David Aylmer

COO

43,333

91,526

0.4%

Β 

These awards have been made under the Eagle Eye Solutions Plc Long Term Incentive Plan scheme. Each option has an exercise price of 1p per share.

Recognising the progress made by the Company under Tim Mason's guidance, the Remuneration Committee of the Company have awarded 221,679 options to him which vest in accordance with the previous year's Long Term Incentive Plan performance criteria, vesting between 30 June 2019 and 30 June 2020 subject to revenue performance criteria and a minimum share price performance hurdle of 106.0p, the Company's share price when the other options under the previous year's Long Term Incentive Plan were granted.

All other options above have been granted under the current year's Long Term Incentive Plan performance criteria, vesting between 30 June 2020 and 30 June 2021 subject to revenue performance criteria and also have a minimum share price performance hurdle, based on the Company's share price at the date of grant of 232.5p.

Following the new grant of options and assuming all vesting criteria is met, the fully diluted number of Ordinary Shares would be 28,541,676; of which the total number of Ordinary Shares over which options currently issued and outstanding represent 11.0% of the fully diluted number of Ordinary Shares.

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Β 

Β 

Name

1. Tim Mason

2. Steve Rothwell

3. Lucy Sharman-Munday

4. Helen Slaven

5. David Aylmer

2

Reason for the notification

a)

Β 

Β 

Position/status

1. Chief Executive Officer

2. Chief Technology Officer

3. Chief Financial Officer

4. Chief Sales Officer

5. Chief Operating Officer

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Eagle Eye Solutions Group plc

b)

LEI

2138002S1AIBVVMZ7A21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Β 

Identification code

Β 

Β 

Options over Ordinary shares of 1p each

Β 

GB00BKF1YD83

b)

Nature of transaction

Grant of Options

Β 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

1. Β£0.01 exercise price per share

2. Β£0.01 exercise price per share

3. Β£0.01 exercise price per share

4. Β£0.01 exercise price per share

5. Β£0.01 exercise price per share

1. 305,550

2. 47,527

3. 47,527

4. 47,527

5. 43,333

Aggregated information

- Aggregated volume

- Price

Β 

491,464 options

Β£4,914.64 combined exercise price

e)

Date of the transaction

9 November 2017

f)

Place of the transaction

Outside of a trading venue

Β 

Β 

For further information, please contact:

Tim Mason, Chief Executive Officer

Lucy Sharman-Munday, Chief Financial Officer

Tel: 0844 824 3686

Β 

Investec (Nominated Advisor and Broker)

Corporate Finance: David Anderson / Sebastian Lawrence

Tel: 020 7597 5970

Corporate Broking: Matt Lewis / Rob Baker

Β 

Hudson Sandler

Nick Lyon/Hattie O'Reilly

Tel: 020 7796 4133

Β 

Information on Eagle Eye

www.eagleeye.com

Β 

Eagle EyeΒ is a leading SaaS technology company that allows businesses to create a real-time connection with their customers.

Β 

The Company's digital marketing platform, Eagle Eye AIR, enables the secure, real-time, multi-channel issuance, management and redemption of digital promotions and rewards, replacing previously used paper-based methods. Our Eagle Eye platform creates a network effect between merchants, distributors and brands enabling stronger connections and value to all parties. Through our four products we enable brands and merchants to reduce cost, improve their customer offer and accelerate their innovation.

Β 

The Company's current customer base comprises leading names in UK grocery, retail and hospitality including John Lewis, Asda, J Sainsbury, Greggs, JD Sports, Ladbrokes, Marks & Spencer, Mitchells & Butlers, Pizza Express, Tesco and Thomas Pink.

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCOKKDPPBDDFDD
Date   Source Headline
28th May 20267:00 amRNSSale of shares from treasury
21st May 20262:47 pmRNSPDMR shareholding & issue of equity - replacement
21st May 20261:35 pmRNSPDMR shareholding and issue of equity
21st May 20267:00 amRNSCapital Markets Day
27th Apr 20267:00 amRNSNotice of Capital Markets Day
24th Apr 202612:30 pmRNSPDMR Shareholding
23rd Apr 20268:11 amRNSPDMR shareholding and issue of equity
31st Mar 20262:02 pmRNSPCA Shareholding
20th Mar 202610:36 amRNSDirector/PDMR Shareholding
17th Mar 202612:11 pmRNSIssue of Equity
17th Mar 20267:00 amRNSHalf Year Results
17th Mar 20267:00 amRNSHalf Year Results
6th Mar 20267:00 amRNSTransaction in Own Shares & Programme Completion
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20265:18 pmRNSNotification of major holdings
2nd Mar 20262:43 pmRNSHolding(s) in Company
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:00 amRNSTransaction in Own Shares
25th Feb 20267:00 amRNSTransaction in Own Shares
24th Feb 20267:00 amRNSTransaction in Own Shares
20th Feb 20267:00 amRNSTransaction in Own Shares
18th Feb 20267:00 amRNSTransaction in Own Shares
12th Feb 20263:32 pmRNSDirector/PDMR Shareholding
12th Feb 202610:59 amRNSDirector/PDMR Shareholding
12th Feb 20267:00 amRNSTransaction in Own Shares
11th Feb 20267:00 amRNSTransaction in Own Shares
10th Feb 20267:00 amRNSTransaction in Own Shares
9th Feb 20267:00 amRNSTransaction in Own Shares
6th Feb 20267:00 amRNSTransaction in Own Shares
5th Feb 20267:00 amRNSTransaction in Own Shares
4th Feb 20267:00 amRNSTransaction in Own Shares
3rd Feb 20267:00 amRNSTransaction in Own Shares
2nd Feb 20267:00 amRNSExtension of Share Buyback Long Stop Expiry Date
29th Jan 20267:00 amRNSTransaction in Own Shares
26th Jan 20267:00 amRNSAppointment of Nominated Adviser and Joint Broker
23rd Jan 20263:48 pmRNSDirector Declaration Update
20th Jan 20267:00 amRNSH1 FY26 Trading Update and Notice of Results
20th Jan 20267:00 amRNSTransaction in Own Shares
19th Jan 20267:00 amRNSTransaction in Own Shares
13th Jan 20267:00 amRNSMajor US multi-year contract win
12th Jan 20267:00 amRNSTransaction in Own Shares
8th Jan 20267:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
31st Dec 20257:00 amRNSTransaction in Own Shares
29th Dec 20257:00 amRNSTransaction in Own Shares
29th Dec 20257:00 amRNSTransaction in Own Shares
19th Dec 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.